Skip Nav Destination
Issues
15 April 2010
-
Cover Image
Cover Image
Automated quantitative analysis (AQUA) of STAT3 in head and neck squamous cell carcinoma (HNSCC) may be a more reliable indicator of STAT3 activation status. The cover features a pseudocolored colocalization image demonstrating compartment assignment. Cytokeratin-Cy3 (green) was used to define the nonnuclear compartment; 4',6-Diamidino-2- phenylindole (DAPI; blue) was used to define the nuclear compartment. For details, see the article by Pectasides and colleagues on page 2427 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
Molecular Pathways
Human Cancer Biology
Synergistic Antitumor Effect of the Activated PPARγ and Retinoid Receptors on Human Osteosarcoma
Bai-Cheng He; Liang Chen; Guo-Wei Zuo; Wenli Zhang; Yang Bi; Jiayi Huang; Yi Wang; Wei Jiang; Qing Luo; Qiong Shi; Bing-Qiang Zhang; Bo Liu; Xia Lei; Jinyong Luo; Xiaoji Luo; Eric R. Wagner; Stephanie H. Kim; Connie J. He; Yawen Hu; Jikun Shen; Qixin Zhou; Farbod Rastegar; Zhong-Liang Deng; Hue H. Luu; Tong-Chuan He; Rex C. Haydon
Crosstalk between Mast Cells and Pancreatic Cancer Cells Contributes to Pancreatic Tumor Progression
Matthew J. Strouch; Eric C. Cheon; Mohammad R. Salabat; Seth B. Krantz; Elias Gounaris; Laleh G. Melstrom; Surabhi Dangi-Garimella; Edward Wang; Hidayatullah G. Munshi; Khashayarsha Khazaie; David J. Bentrem
The EPHB6 Receptor Tyrosine Kinase Is a Metastasis Suppressor That Is Frequently Silenced by Promoter DNA Hypermethylation in Non–Small Cell Lung Cancer
Jun Yu; Etmar Bulk; Ping Ji; Antje Hascher; Moying Tang; Ralf Metzger; Alessandro Marra; Hubert Serve; Wolfgang E. Berdel; Rainer Wiewroth; Steffen Koschmieder; Carsten Müller-Tidow
Cancer Therapy: Preclinical
CK2 Modulation of NF-κB, TP53, and the Malignant Phenotype in Head and Neck Cancer by Anti-CK2 Oligonucleotides In vitro or In vivo via Sub–50-nm Nanocapsules
Matthew S. Brown; Oumou T. Diallo; Michael Hu; Reza Ehsanian; Xinping Yang; Pattatheyil Arun; Hai Lu; Vicci Korman; Gretchen Unger; Khalil Ahmed; Carter Van Waes; Zhong Chen
Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
Asima Mukhopadhyay; Ahmed Elattar; Aiste Cerbinskaite; Sarah J. Wilkinson; Yvette Drew; Suzanne Kyle; Gerrit Los; Zdenek Hostomsky; Richard J. Edmondson; Nicola J. Curtin
Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors
Fariba Némati; Xavier Sastre-Garau; Cécile Laurent; Jérôme Couturier; Pascale Mariani; Laurence Desjardins; Sophie Piperno-Neumann; Olivier Lantz; Bernard Asselain; Corine Plancher; Delphine Robert; Isabelle Péguillet; Marie-Hélène Donnadieu; Ahmed Dahmani; Marie-Andrée Bessard; David Gentien; Cécile Reyes; Simon Saule; Emmanuel Barillot; Sergio Roman-Roman; Didier Decaudin
Preclinical Evidence that Use of TRAIL in Ewing's Sarcoma and Osteosarcoma Therapy Inhibits Tumor Growth, Prevents Osteolysis, and Increases Animal Survival
Gaëlle Picarda; François Lamoureux; Loïc Geffroy; Pascal Delepine; Tristan Montier; Karine Laud; Franck Tirode; Olivier Delattre; Dominique Heymann; Françoise Rédini
Imaging, Diagnosis, Prognosis
Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment
Higinio Dopeso; Silvia Mateo-Lozano; Elena Elez; Stefania Landolfi; Francisco Javier Ramos Pascual; Javier Hernández-Losa; Rocco Mazzolini; Paulo Rodrigues; Sarah Bazzocco; Maria Josep Carreras; Eloy Espín; Manel Armengol; Andrew J. Wilson; John M. Mariadason; Santiago Ramon y Cajal; Josep Tabernero; Simo Schwartz, Jr.; Diego Arango
ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction
Jan C. Brase; Marcus Schmidt; Thomas Fischbach; Holger Sültmann; Hans Bojar; Heinz Koelbl; Birte Hellwig; Jörg Rahnenführer; Jan G. Hengstler; Mathias C. Gehrmann
Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma
Kazuo Koyanagi; Steven J. O'Day; Peter Boasberg; Michael B. Atkins; He-Jing Wang; Rene Gonzalez; Karl Lewis; John A. Thompson; Clay M. Anderson; Jose Lutzky; Thomas T. Amatruda; Evan Hersh; Jon Richards; Jeffrey S. Weber; Dave S.B. Hoon
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
Anna K. Nowak; Roslyn J. Francis; Michael J. Phillips; Michael J. Millward; Agatha A. van der Schaaf; Jan Boucek; Arthur W. Musk; Melanie J. McCoy; Amanda Segal; Peter Robins; Michael J. Byrne
Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis
Eirini Pectasides; Ann-Marie Egloff; Clarence Sasaki; Panteleimon Kountourakis; Barbara Burtness; George Fountzilas; Urania Dafni; Thomas Zaramboukas; Theodoros Rampias; David Rimm; Jennifer Grandis; Amanda Psyrri
Cancer Therapy: Clinical
Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494
Jane N. Winter; Shuli Li; Vikas Aurora; Daina Variakojis; Beverly Nelson; Maryla Krajewska; Lijun Zhang; Thomas M. Habermann; Richard I. Fisher; William R. Macon; Mukesh Chhanabhai; Raymond E. Felgar; Eric D. Hsi; L. Jeffrey Medeiros; James K. Weick; Edie A. Weller; Ari Melnick; John C. Reed; Sandra J. Horning; Randy D. Gascoyne
A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer
Eric B. Haura; Alejandro D. Ricart; Timothy G. Larson; Philip J. Stella; Lyudmila Bazhenova; Vincent A. Miller; Roger B. Cohen; Peter D. Eisenberg; Paulina Selaru; Keith D. Wilner; Shirish M. Gadgeel
A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors
Razelle Kurzrock; Amita Patnaik; Joseph Aisner; Terri Warren; Stephen Leong; Robert Benjamin; S. Gail Eckhardt; Joseph E. Eid; Gerard Greig; Kai Habben; Cinara D. McCarthy; Lia Gore
Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study
Federico Rojo; Elías Gracias; Nadia Villena; Teresa Cruz; Josep Maria Corominas; Irene Corradino; Mercedes Cedeño; Clara Campas; Marta Osorio; Normando Iznaga; Beatriz Bellosillo; Ana Rovira; Silvia Marsoni; Pere Gascon; Sergio Serrano; Cristiana Sessa; Tania Crombet; Joan Albanell
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds